Rivaroxaban added to immune-calming treatment for leg vein clots in Behcet's disease
Tests adding rivaroxaban to immunosuppressive treatment for leg vein clots in Behcet's disease.
Key facts
- Who runs it
- Marmara University
- Where
- Türkiye2 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Immunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 110 people, planned
- Started
- 30 Apr 2025
- Expected to end
- 1 Apr 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Placebo plus immunosuppression
- Rivaroxaban plus immunosupression
- Record updated
- 13 April 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Behçet's Disease who have a new blood clot in a leg vein. It compares immune-lowering medicine alone with the same medicine plus the blood thinner Rivaroxaban.
- Age
- 18 to 50 years
- Sex
- All sexes can join. Women cannot be pregnant or breastfeeding. Women who could become pregnant must use effective birth control.
- Disease stage
- Behçet's Disease diagnosed by the International Study Group (ISG) criteria. A blood clot in a leg vein, confirmed within the last 14 days before being assigned to a group. The clot is shown by ultrasound, venography, CT or MR angiography.
- Earlier treatment
- No earlier blood vessel involvement, or no earlier immune-lowering treatment for it. No immune-lowering drugs (azathioprine, mycophenolate mofetil, cyclosporine, cyclophosphamide, TNF inhibitors, interferon-gamma) in the last 6 months. No corticosteroids for more than 3 months for skin and mouth symptoms. No heparin-type drugs or fondaparinux for more than 48 hours, and no more than one dose of vitamin K antagonists. No clot removal, vena cava filter or clot-dissolving treatment for this clot.
Main reasons for not taking part
- Any aneurysm (a bulging blood vessel)
- Active bleeding or high bleeding risk, or known clotting disorders
- Creatinine clearance <30 ml/min or severe liver disease
- Cancer in the last 5 years, with some skin and cervix exceptions
- Positive test for Hepatitis B or C, or known HIV-1 infection
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Participants must meet the following criteria to be eligible for the study:; Age between 18-50 years old. Diagnosed with Behçet's Disease according to the International Study Group (ISG) criteria; No prior vascular involvement or no previous immunosuppressive therapy for vascular involvement; Confirmed venous thrombosis in the lower extremity within the last 14 days before randomization; Venous thrombosis diagnosis confirmed by:; Non-compressible venous segment in ultrasound, OR A significant (>4 mm) increase in thrombus diameter in an already abnormal segment, OR New intraluminal filling defect on venography, CT, or MR angiography; Female participants must:; Not be pregnant or breastfeeding. Use effective contraception if of childbearing potential. Be postmenopausal (no menses for at least 1 year) or have undergone surgical sterilization; Ability to provide written informed consent and comply with study requirements
Who cannot take part
- Participants will be excluded if they meet any of the following criteria:; Presence of any aneurysm. Chronic multisystemic disease other than Behçet's Disease. History of intolerance to Rivaroxaban. Use of immunosuppressive drugs (azathioprine, mycophenolate mofetil, cyclosporine, cyclophosphamide, TNF inhibitors, or interferon-gamma) within the last 6 months; Prolonged corticosteroid use (>3 months) for Behçet's Disease mucocutaneous symptoms; Prior anticoagulant therapy:; Low molecular weight heparin, fondaparinux, or unfractionated heparin for >48 hours before randomization; More than one dose of vitamin K antagonists before randomization. Thrombectomy, vena cava filter placement, or fibrinolytic therapy for the current thrombotic episode; Planned administration of a live vaccine within 30 days after randomization. Clinically significant acute or uncontrolled chronic diseases (e.g., cardiovascular, pulmonary, hematologic, gastrointestinal, hepatic, renal, neurological, malignancy, or infectious diseases) that may interfere with study results; Planned surgical procedure or significant medical condition deemed unsuitable for the study by the investigator; History of malignancy within the last 5 years (except adequately treated basal or squamous cell carcinoma or carcinoma in situ of the cervix); Renal impairment (Creatinine clearance <30 ml/min). Severe liver disease (e.g., acute hepatitis, active chronic hepatitis, cirrhosis, or ALT >3 times the upper limit); Active bleeding or high bleeding risk contraindicating anticoagulant therapy. Uncontrolled hypertension (SBP >180 mmHg or DBP >110 mmHg). Severe anemia (Hemoglobin <10 mg/dL). Women who are pregnant, breastfeeding, or of childbearing potential without contraception; Use of strong CYP3A4 inhibitors or inducers (e.g., protease inhibitors, systemic ketoconazole, rifampin, carbamazepine, phenytoin); Participation in another experimental drug study within the last 30 days. Life expectancy of less than 3 months. History of serious infections within the last 60 days (e.g., bacterial endocarditis, tuberculosis, opportunistic infections); Active substance or alcohol abuse or history of substance dependence within the last year; Positive screening for Hepatitis B surface antigen, Hepatitis C antibody, or known HIV-1 infection; Known coagulation disorders or laboratory abnormalities (e.g., DMID toxicity scale Grade 3 or higher); History of suicidal behavior in the last 6 months or suicidal ideation (C-SSRS type 4 or 5) in the last 2 months
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 50 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is a Phase III, multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial investigating the treatment of lower extremity venous thrombosis associated with Behçet's Disease. The study compares the effectiveness and safety of immunosuppressive therapy alone versus immunosuppressive therapy combined with oral anticoagulation (Rivaroxaban).
The 2 groups in the trial
- Immunosuppressive Therapy + PlaceboPlacebo, for comparison
Azathioprine (2.5 mg/kg/day, maximum 200 mg/day, oral) Methylprednisolone (0.5 mg/kg/day, oral, tapered over 12 weeks according to protocol) + Placebo
Treatment: Placebo plus immunosuppression
- Immunosuppressive Therapy + RivaroxabanExisting treatment, for comparison
Azathioprine (2.5 mg/kg/day, maximum 200 mg/day, oral) Methylprednisolone (0.5 mg/kg/day, oral, tapered over 12 weeks according to protocol), plus Rivaroxaban (20 mg/day, oral, for 12 months)
Treatment: Rivaroxaban plus immunosupression
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Immunosuppressive Therapy Alone Versus Immunosuppressive Therapy Plus Oral Anticoagulation in the Treatment of Lower Extremity Venous Thrombosis Associated With Behcet's Disease
- Plain-language title
- Rivaroxaban added to immune-calming treatment for leg vein clots in Behcet's diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT06925698, who can take part
- Record updated
- 13 April 2025